Literature DB >> 10098760

Prognostic implications of various models for calculation of S-phase fraction in 259 patients with soft tissue sarcoma.

P Gustafson1, B Baldetorp, M Fernö, M Akerman.   

Abstract

The S-phase fraction (SPF) in flow cytometric DNA histograms in soft tissue sarcoma (STS) can be calculated in various ways. The traditional planimetric method of Baisch has been shown to be prognostic, but is hampered by a failure rate of around 40%. We therefore tested other models to see if this rate could be decreased with retained prognostic value. In 259 STS of the locomotor system the SPF was calculated according to Baisch and with commercial parametric MultiCycle software using different corrections for background. Using the Baisch model, 159 histograms could be evaluated for SPF. The 5-year metastasis-free survival rate (MFSR) was 0.94 for the low-risk group (defined with SPF), and 0.53 for the high-risk group. In the low-risk group, four of the seven patients who developed metastasis did so after 5 years Using the MultiCycle software, SPF could be calculated in 253 tumours. Depending on type of background correction used, the 5-year MFSR varied between 0.67 and 0.82 for the low-risk group, and between 0.47 and 0.53 for the high-risk group. The late metastasis pattern in the low-risk group was never seen using the MultiCycle software. We conclude that in paraffin archival material, calculation of SPF according to Baisch is preferable in clinical use due to better separation between low-risk and high-risk groups, and also the possibility to identify patients who metastasize late.

Entities:  

Mesh:

Year:  1999        PMID: 10098760      PMCID: PMC2362255          DOI: 10.1038/sj.bjc.6690193

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  DNA histogram debris theory and compensation.

Authors:  C B Bagwell; S W Mayo; S D Whetstone; S A Hitchcox; D R Baker; D J Herbert; D L Weaver; M A Jones; E J Lovett
Journal:  Cytometry       Date:  1991

2.  S-phase fraction assessed by a variant of the rectangular model adapted to the flow-cytometric DNA histogram profile.

Authors:  O Stål; B Baldetorp
Journal:  Cytometry       Date:  1998-12-01

3.  Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm.

Authors:  B Baldetorp; M Dalberg; U Holst; G Lindgren
Journal:  Cytometry       Date:  1989-11

Review 4.  Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors.

Authors:  D E Merkel; W L McGuire
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

5.  Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates.

Authors:  B Baldetorp; P O Bendahl; M Fernö; K Alanen; U Delle; U Falkmer; B Hansson-Aggesjö; T Höckenström; A Lindgren; L Mossberg
Journal:  Cytometry       Date:  1995-06-15

6.  Cementation pressure in arthroplasty. In vitro study of cement penetration into femoral heads.

Authors:  R Juliusson; J Arve; L Ryd
Journal:  Acta Orthop Scand       Date:  1994-04

7.  Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology.

Authors:  T V Shankey; P S Rabinovitch; B Bagwell; K D Bauer; R E Duque; D W Hedley; B H Mayall; L Wheeless; C Cox
Journal:  Cytometry       Date:  1993

8.  S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome.

Authors:  R L Huuhtanen; C P Blomqvist; T A Wiklund; M J Virolainen; A I Elomaa; Y Pan; B Tribukait
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

9.  Evaluation of flow cytometric data of human tumours. Correction procedures for background and cell aggregations.

Authors:  H P Beck
Journal:  Cell Tissue Kinet       Date:  1980-03

10.  Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis.

Authors:  O Bratt; H Anderson; E Bak-Jensen; B Baldetorp; R Lundgren
Journal:  Urology       Date:  1996-02       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.